Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al. Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond, E, E Perez, J Bryant, V Suman, C Geyer, N Davidson, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Widespread use of selective estrogen receptor modulators could result in an approximately 30% decrease in breast cancer.  
  • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
  • Following the current path, the colon cancer incidence rate will increase by 31.8% between 2003 and 2023 (447,000 people). If an alternative path is taken, there will be 17.7% (79,000…  
  • Incidence rates for colorectal cancer have been decreasing since 1985, from 66 to 52 per 100,000 in 2002.  
  • A prostate cancer vaccine, sipleucel-T immunotherapy, in men with metastatic castration-resistant prostate cancer, reduced the risk of death by 22 percent compared to placebo, and represented a 4.2 month improvement in…